
AUDIO JOURNAL OF ONCOLOGY PM 2.5 Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer
Charles Swanton FRCP BSc PhD
An Audio Journal of Oncology episode reports on research linking particulate air pollution (PM 2.5) to non-small cell lung cancer in never smokers. Professor Charles Swanton's group identified interleukin 1-beta as a key cytokine released by epithelial cells, transforming pre-existing mutations into tumors. This significant finding, presented at the 2022 ESMO Congress, offers new insights into global cancer prevention mechanisms.
PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of the European Society for Medical Oncology (ESMO).
Charles Swanton FRCP BSc PhD, Professor and Senior Group Leader of the Francis Crick Institute, Consultant Oncologist at University College London Hospital specializing in Thoracic Oncology and ESMO Scientific Co-Chair, told the Audio Journal of Oncology that prevention was better than cure wherever possible, and that the oncogenic mechanisms his group’s research had uncovered held important keys to reducing the cancer burden globally.
https://cslide.ctimeetingtech.com/esmo2022/attendee/confcal/session/calendar/2022-09-09
Swanton’s group had investigated the relationship between air pollution and lung cancer in never smokers. “We’ve tried to establish how air pollution causes lung cancer,” he told OT. “Through a series of steps involving animal models and human analyses we’ve found that air pollution results in the release of a cytokine called: interleukin 1-beta from epithelial cells in the lung, that generates and transforms cells with pre-existing mutations—that occur normally due to aging—into tumor cells.”
He discussed his findings during the ESMO congress in Paris with the Audio Journal of Oncology’s Peter Goodwin.
Tags
Next in ESMO
All 51 interviewsInterview 7 of 51

Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f
Related Episodes

Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy

Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting

PD-L1 Checkpoint Inhibitor Immunotherapy Boosts Survival in Lung Cancer
The Audio Journal of Oncology Reporting from the 2016 Congress of the European Society of Medical Oncology COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab e